Saturday 17 October 2026
Export GPCR’s income statement to Excel — free account
Structure Therapeutics Inc. Sponsored ADR
GPCR Healthcare Biotechnology
In the quarter to June 2026, EPS fell 36.4% and free cash flow fell 119.2%, each against the same quarter a year earlier.
20.95
1.24
−5.59%
Follow GPCR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
Current Ratio |
24.81 | 24.74 | 19.14 | 7.16 | 12.62 | 12.64 |
Net Debt/EBITDA |
8.27 | 5.62 | 4.56 | 1.71 | 2.86 | 2.34 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.72% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.57 | 0.95 | 0.89 | 0.87 | 0.73 | 0.89 |
Capex/Depreciation |
(2.15) | (1.30) | (6.86) | 0.25 | (8.26) | 0.00 |
Interest Coverage |
— | — | — | — | — | (189.35) |
| (11.86%) | (18.60%) | (53.06%) | 58.75% | 100.37% | 0.00% | |
| (11.35%) | (17.69%) | (30.91%) | (50.56%) | (58.41%) | 0.00% | |
ROIC |
(157.24%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(9.33%) | (14.27%) | (19.82%) | (65.14%) | (43.00%) | (45.06%) |
Average Days of Receivables |
0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Free Cash Flow per Share |
(3.81) | (2.24) | (2.22) | (14.48) | (12.29) | (0.39) |
Cash per Share |
24.43 | 16.78 | 12.72 | 28.43 | 39.54 | 1.02 |
Shareholders Equity per Share |
25.61 | 16.43 | 12.33 | 26.55 | 37.67 | 0.97 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
25.61 | 16.43 | 12.33 | 26.55 | 37.67 | 0.97 |
Free Cash Flow |
(225.81) | (117.93) | (81.65) | (46.27) | (33.37) | (14.31) |
Working Capital |
1,507.02 | 855.19 | 448.87 | 80.08 | 100.59 | 35.38 |
Capital Expenditures |
(3.61) | (1.29) | (2.17) | (0.15) | (1.21) | (0.02) |
Net Current Asset Value |
1,502.76 | 852.72 | 444.56 | 80.08 | 100.32 | 35.25 |
| Other line items | ||||||
Quick Ratio |
24.43 | 24.53 | 18.89 | 6.98 | 12.39 | 12.32 |
Depreciation/Fixed assets |
0.25 | 0.29 | 0.10 | (0.61) | 0.12 | 0.07 |
Cash ROIC |
(7.62%) | (6.74%) | (8.87%) | (26.34%) | (15.92%) | (19.53%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27,867.75 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(3.75) | (2.22) | (2.16) | (14.44) | (11.85) | (0.39) |
Capex per Share |
(0.06) | (0.02) | (0.06) | (0.05) | (0.44) | 0.00 |
Average Payables |
10.94 | 6.38 | 5.38 | 4.75 | 2.51 | — |
Average Assets |
1,243.62 | 692.67 | 289.93 | 104.50 | 74.93 | — |
Average Common Equity |
1,190.61 | 658.90 | 168.91 | (89.94) | (43.60) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates